Citigroup’s Innate Pharma IPHA Stock Holding History

Citigroup’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-54	Closed	-$201	–	5677
2022 Q4	$201	Hold	54	–	–	﹤0.01%	5597
2022 Q3	$0	Sell	54 -1	-2%	-$3	﹤0.01%	6073
2022 Q2	$0	Hold	55	–	–	﹤0.01%	6427
2022 Q1	$0	Buy	55 +11	+25%	+$41	﹤0.01%	6466
2021 Q4	$0	Buy	+44	New	+$234	﹤0.01%	5972

Other funds holding IPHA

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Citigroup's IPHA Position: Q1 2023 in Review

Citigroup sold out of Innate Pharma (IPHA) in Q1 2023, closing a stake of 54 shares — an estimated $201 sold.

Citigroup first reported a position in IPHA in Q4 2021 and held it in 5 quarters. The position peaked at $201 in Q4 2022. 9 funds tracked by Wall St. Rank hold IPHA as of Q1 2023.

Citigroup reported no remaining Innate Pharma position as of Q1 2023 after selling out during the quarter.
Citigroup sold 54 Innate Pharma shares in Q1 2023, an estimated $201.
Citigroup first reported a position in Innate Pharma in Q4 2021 and held it in 5 quarters.
Citigroup's Innate Pharma position peaked at $201 in Q4 2022.
9 funds tracked by Wall St. Rank held Innate Pharma as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.